Evidence map›Paper›PMID 26191276›Full record

ArticleInternational journal of clinical and experimental pathology2015

Prognostic and predictive values of Nrf2, Keap1, p16 and E-cadherin expression in ovarian epithelial carcinoma.

Phui-Ly Liew, Chun-Sen Hsu, Wei-Min Liu, Yu-Chieh Lee, Yi-Chih Lee, Chi-Long Chen

Open access · greenAbstract readComparative Study
PubMed Full text at PMC
In one paragraph

Article in International journal of clinical and experimental pathology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 1 pooled it
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Role of NRF2 in Ovarian Cancer.Antioxidants (Basel, Switzerland) · 2022
    Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. NRF2 addiction in cancer cells.Cancer science · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Phui-Ly LiewDepartment of Pathology, Shuang Ho Hospital, Taipei Medical University Taipei, Taiwan ; Department of Pathology, School of Medicine, College of Medicine, Taipei Medical University Taipei, Taiwan.
Chun-Sen HsuDepartment of Obstetrics and Gynecology, Wan Fang Hospital, Taipei Medical University Taipei, Taiwan.
Wei-Min LiuDepartment of Obstetrics and Gynecology, Taipei Medical University Hospital, Taipei Medical University Taipei, Taiwan.
Yu-Chieh LeeGraduate Institute of Medical Sciences, Taipei Medical University Taipei, Taiwan.
Yi-Chih LeeDepartment of International Business, Chien Hsin University of Science and Technology Zhongli City, Taiwan.
Chi-Long ChenDepartment of Pathology, School of Medicine, College of Medicine, Taipei Medical University Taipei, Taiwan ; Department of Pathology, Taipei Medical University Hospital, Taipei Medical University Taipei, Taiwan.
Taipei Medical University Hospital · TWChien Hsin University of Science and Technology · TWTaipei Medical University · TWWan Fang Hospital · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesDespite considerable interest in the Nuclear factor-erythroid 2-related factor 2 (Nrf2)/Kelch-like ECH-associated protein-1 (Keap1), p16 and epithelial cadherin (E-cadherin) activation in carcinoma progression, contradictory results regarding association of Nrf2/Keap1/E-cadherin and p16 expression with clinico-pathological features and prognosis have been reported. The predictive value of these markers in ovarian carcinoma is unknown. METHODS/MATERIALS: In this retrospective study, 108 cases were evaluated immunohistochemically with antibodies to Nrf2, Keap1, estrogen receptor (ER), p16 and E-cadherin. The results were compared with histological and clinical data, disease-free survival (DFS) and overall survival (OS).

resultsA cohort of 108 ovarian carcinomas (47 serous, 23 mucinous, 13 endometrioid and 25 clear cell), including 68 FIGO stage I-II cases and 40 FIGO stage III-IV cases was studied. The age of patients (P=0.005), FIGO stage (P<0.001), immunohistochemical expression of Keap1 (P<0.000), E-cadherin (P=0.045), p53 (P=0.003), p16 (P<0.001) and ER (P=0.004) were significant factors between different histological subtypes. Patients with serous carcinoma were older in age, presented with more advanced stage disease, worst prognosis, highest Keap1 expression and least percentage of E-cadherin immunoreactivity. In univariate analysis, FIGO staging (P=0.000 for DFS; P=0.000 for OS), Nrf2 (P=0.010 for DFS; P=0.001 for OS), and p16 (P=0.004 for DFS; P=0.019 for OS) were associated with worse prognosis. After multivariate analysis, FIGO staging and Nrf2 remained significance prognostic factors.

conclusionsThere were differences in the expression of Nrf2, Keap1, p16 and E-cadherin between different ovarian carcinoma subtypes. In multivariate analysis, FIGO stage and Nrf2 expression were associated with poorer DFS and OS.

Indexed as

AdultAgedAged, 80 and overAge FactorsAntigens, CDBiomarkers, TumorCadherinsCarcinoma, Ovarian EpithelialCyclin-Dependent Kinase Inhibitor p16Disease-Free SurvivalFemaleHumansImmunohistochemistryIntracellular Signaling Peptides and ProteinsKaplan-Meier EstimateKelch-Like ECH-Associated Protein 1Antigens, CDBiomarkers, TumorCadherinsCDH1 protein, humanCyclin-Dependent Kinase Inhibitor p16Intracellular Signaling Peptides and ProteinsKEAP1 protein, humanKelch-Like ECH-Associated Protein 1NFE2L2 protein, humanNF-E2-Related Factor 2E-CadherinKeap1Nrf2ovarian cancerp16

Identifiers

PMID26191276
PMCPMC4503147
OpenAlexW1615295197

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.